Upsher-Smith announced the recent launch of Mesalamine extended-release Capsules, USP 375 mg. The mesalamine capsule market had U.S. sales of approximately $105M for the 12 months ending June 2023, according to IQVIA. Upsher-Smith's Mesalamine Extended-Release Capsules are AB-rated to APRISO® (mesalamine) extended-release capsules.
Mesalamine is used to treat ulcerative colitis (a condition which causes swelling and sores in the lining of the colon and also to maintain improvement of ulcerative colitis symptoms. Mesalamine is considered an anti-inflammatory agent.